Who are Bimatoprost Solution 2's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rocklatan 0.02%-0.005% Ophthalmic Solution, Preservative-free latanoprost 50µg/ml, tafluprost/timolol, Propess® (dinoprostone), Bimatoprost 0.01%, latanoprost 0.005% (Xalatan).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bimatoprost-solution-2.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Bimatoprost Solution 2 — Competitive Intelligence Brief

Bimatoprost Solution 2 (Bimatoprost Solution 2) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin analogue. Area: Ophthalmology.

phase 2 Prostaglandin analogue FP receptor Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Bimatoprost Solution 2 (Bimatoprost Solution 2) — Allergan. Prostaglandin F2α analogue

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Bimatoprost Solution 2 TARGET	Bimatoprost Solution 2	Allergan	phase 2	Prostaglandin analogue	FP receptor
Rocklatan 0.02%-0.005% Ophthalmic Solution	Rocklatan 0.02%-0.005% Ophthalmic Solution	Eye Centers of Southeast Texas	marketed	Prostaglandin analog / Rho kinase inhibitor combination	Prostaglandin F receptor (FP receptor) / Rho kinase (ROCK)
Preservative-free latanoprost 50µg/ml	Preservative-free latanoprost 50µg/ml	Medical University of Vienna	marketed	Prostaglandin F receptor agonist	FP receptor (prostaglandin F receptor)
tafluprost/timolol	tafluprost/timolol	Fondazione G.B. Bietti, IRCCS	marketed	Prostaglandin analog / beta-blocker combination	FP receptor (tafluprost); beta-2 adrenergic receptor (timolol)
Propess® (dinoprostone)	Propess® (dinoprostone)	University Hospital, Clermont-Ferrand	marketed	Prostaglandin F2α analog	Prostaglandin F receptor (FP receptor)
Bimatoprost 0.01%	Bimatoprost 0.01%	Allergan	marketed	Prostaglandin F analog	Prostaglandin F receptor (FP receptor)
latanoprost 0.005% (Xalatan)	latanoprost 0.005% (Xalatan)	Pfizer	marketed	Prostaglandin F receptor agonist	FP receptor (prostaglandin F receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin analogue class)

Tampere University Hospital · 2 drugs in this class
Allergan · 1 drug in this class
Hawler Medical University · 1 drug in this class
Ain Shams University · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
Santen Pharmaceutical Co., Ltd. · 1 drug in this class
Mati Therapeutics Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bimatoprost Solution 2 — Competitive Intelligence Brief. https://druglandscape.com/ci/bimatoprost-solution-2. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab